Dystrophic Epidermolysis Bullosa Treatment Market:
Introduction
According to the report, the global dystrophic
epidermolysis bullosa treatment market was valued over
US$ 412 Mn in 2019 and is projected to expand at a CAGR of ~5%
from 2020 to 2030. Dystrophic epidermolysis bullosa (DEB) is the second most
common form of epidermolysis bullosa. The prevalence of DEB varies from 1
per 49,000 inhabitants in Scotland to 1 per 420,168 in
the U.S. According to the U.S. National Library of Medicine, the prevalence of
recessive and dominant dystrophic epidermolysis bullosa is estimated at 3.3 per
million people. North America dominated the global dystrophic epidermolysis
bullosa treatment market in 2019 and the trend is anticipated to continue
during the forecast period. The rise in population suffering from various
diseases in North America has increased the number of patients visiting
hospitals. Hence, the consumption of dystrophic epidermolysis bullosa treatment
products is expected to increase during the forecast period. North America’s
large share of the global dystrophic epidermolysis bullosa treatment market can
be attributed to high cost of biologic drugs compared to other regions. It is a
key target region for all players in the global dystrophic epidermolysis
bullosa treatment market. Asia Pacific is likely to be a highly lucrative
market for dystrophic epidermolysis bullosa treatment from 2020 to 2030. The
market in the region is projected to expand at a high CAGR during the forecast
period.
Antibiotics to Dominate Global Market
In terms of treatment type, the global dystrophic epidermolysis bullosa
treatment market has been classified into antibiotics, corticosteroids, opioid
analgesics, anticonvulsant, and others. The antibiotics segment dominated the
global dystrophic epidermolysis bullosa treatment market in 2019 and the trend
is projected to continue during the forecast period. A large number of
antibiotics is in late phases of clinical pipeline trials and are likely to be
commercialized between 2019 and 2025. Anticipated launch and adoption of
antibiotics to address unmet medical needs in dystrophic epidermolysis bullosa
treatment are expected to propel the segment during the forecast period.
Request COVID Analysis on Dystrophic
Epidermolysis Bullosa Treatment Market
–
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=79063
Dominant Dystrophic Epidermolysis Bullosa (DDEB) to
be Highly Lucrative
Based on service provider, the global dystrophic epidermolysis bullosa
treatment market has been bifurcated into dominant dystrophic epidermolysis
bullosa (DDEB) and recessive dystrophic epidermolysis bullosa (RDEB). The
dominant dystrophic epidermolysis bullosa (DDEB) segment dominated the global
dystrophic epidermolysis bullosa treatment market due to large number of
patients suffering from dominant dystrophic epidermolysis bullosa. According to
the National EB Registry, the overall prevalence of EB is 11.07 per one million
live births. The prevalence of DDEB and RDEB is 1.49 and 1.35 per
one million live births, respectively.
Request Customization on Dystrophic Epidermolysis Bullosa Treatment Market
Report –
https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=79063
Competition Landscape
Key players in the global dystrophic epidermolysis bullosa treatment
market include Krystal Biotech, Castle Creek Biosciences, Inc., Abeona
Therapeutics, Inc., Amryt Pharma plc, Wings Therapeutics, Phoenix Tissue
Repair, InMed Pharmaceuticals, Inc., RegeneRx, and Holostem Terapie Avanzate
S.r.l.
Buy Dystrophic
Epidermolysis Bullosa Treatment Market Report-
https://www.transparencymarketresearch.com/checkout.php?rep_id=79063<ype=S
Global Dystrophic Epidermolysis Bullosa Treatment
Market: Segmentation
·
o
o
o
o
o
·
o
o
·
o
o
o
·
·
o
o
·
o
o
o
o
o
o
·
o
o
o
o
o
·
o
o
o
·
o
o
o
About Us
Transparency Market Research is a global market intelligence company, providing
global business information reports and services. Our exclusive blend of
quantitative forecasting and trends analysis provides forward-looking insight
for thousands of decision makers. Our experienced team of analysts,
researchers, and consultants, uses proprietary data sources and various tools
and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research
experts, so that it always reflects the latest trends and information. With a
broad research and analysis capability, Transparency Market Research employs
rigorous primary and secondary research techniques in developing distinctive
data sets and research material for business reports.
Contact
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/
